Alpha 2.0

» Articles » PMID: 19152710

TRIP-Br2 Promotes Oncogenesis in Nude Mice and is Frequently Overexpressed in Multiple Human Tumors

Overview

Overview

Journal J Transl Med

Publisher Biomed Central

Specialties Biomedical Engineering
General Medicine

Date 2009 Jan 21

PMID 19152710

Citations 14

Authors

Authors

Jit Kong Cheong

Lakshman Gunaratnam

Zhi Jiang Zang

Christopher M Yang

Xiaoming Sun

Susan L Nasr

Khe Guan Sim

Bee Keow Peh

Suhaimi Bin Abdul Rashid

Joseph V Bonventre

Manuel Salto-Tellez

Stephen I Hsu

Affiliations

Affiliations

Soon will be listed here.

Abstract

Background: Members of the TRIP-Br/SERTAD family of mammalian transcriptional coregulators have recently been implicated in E2F-mediated cell cycle progression and tumorigenesis. We, herein, focus on the detailed functional characterization of the least understood member of the TRIP-Br/SERTAD protein family, TRIP-Br2 (SERTAD2).

Methods: Oncogenic potential of TRIP-Br2 was demonstrated by (1) inoculation of NIH3T3 fibroblasts, which were engineered to stably overexpress ectopic TRIP-Br2, into athymic nude mice for tumor induction and (2) comprehensive immunohistochemical high-throughput screening of TRIP-Br2 protein expression in multiple human tumor cell lines and human tumor tissue microarrays (TMAs). Clinicopathologic analysis was conducted to assess the potential of TRIP-Br2 as a novel prognostic marker of human cancer. RNA interference of TRIP-Br2 expression in HCT-116 colorectal carcinoma cells was performed to determine the potential of TRIP-Br2 as a novel chemotherapeutic drug target.

Results: Overexpression of TRIP-Br2 is sufficient to transform murine fibroblasts and promotes tumorigenesis in nude mice. The transformed phenotype is characterized by deregulation of the E2F/DP-transcriptional pathway through upregulation of the key E2F-responsive genes CYCLIN E, CYCLIN A2, CDC6 and DHFR. TRIP-Br2 is frequently overexpressed in both cancer cell lines and multiple human tumors. Clinicopathologic correlation indicates that overexpression of TRIP-Br2 in hepatocellular carcinoma is associated with a worse clinical outcome by Kaplan-Meier survival analysis. Small interfering RNA-mediated (siRNA) knockdown of TRIP-Br2 was sufficient to inhibit cell-autonomous growth of HCT-116 cells in vitro.

Conclusion: This study identifies TRIP-Br2 as a bona-fide protooncogene and supports the potential for TRIP-Br2 as a novel prognostic marker and a chemotherapeutic drug target in human cancer.

Citing Articles

Identification of a Novel 4-gene Prognostic Model Related to Neutrophil Extracellular Traps for Colorectal Cancer.

Qian J, Duan J, Cao D Turk J Gastroenterol. 2024; 35(11):849-858.

PMID: 39549020 PMC: 11562497. DOI: 10.5152/tjg.2024.24131.

Establishing and validating an ADCP-related prognostic signature in pancreatic ductal adenocarcinoma.

Zhang D, Cui F, Peng L, Wang M, Yang X, Xia C Aging (Albany NY). 2022; 14(15):6299-6315.

PMID: 35963640 PMC: 9417234. DOI: 10.18632/aging.204221.

REV1 promotes lung tumorigenesis by activating the Rad18/SERTAD2 axis.

Chen Y, Jie X, Xing B, Wu Z, Yang X, Rao X Cell Death Dis. 2022; 13(2):110.

PMID: 35115490 PMC: 8814179. DOI: 10.1038/s41419-022-04567-5.

Microribonucleic Acid-15a-5p Alters Adriamycin Resistance in Breast Cancer Cells by Targeting Cell Division Cycle-Associated Protein 4.

Zhang J, Chen J, Ruan H, Li F, Pang S, Xu Y Cancer Manag Res. 2021; 13:8425-8434.

PMID: 34785950 PMC: 8590962. DOI: 10.2147/CMAR.S333830.

MiR-497-5p down-regulates CDCA4 to restrains lung squamous cell carcinoma progression.

Hu J, Xiang X, Guan W, Lou W, He J, Chen J J Cardiothorac Surg. 2021; 16(1):330.

PMID: 34772428 PMC: 8588708. DOI: 10.1186/s13019-021-01698-2.

References

1.

Salto-Tellez M, Nga M, Han H, Wong A, Lee C, Anuar D . Tissue microarrays characterise the clinical significance of a VEGF-A protein expression signature in gastrointestinal stromal tumours. Br J Cancer. 2007; 96(5):776-82. PMC: 2360083. DOI: 10.1038/sj.bjc.6603551. View

2.

Denchi E, Helin K . E2F1 is crucial for E2F-dependent apoptosis. EMBO Rep. 2005; 6(7):661-8. PMC: 1369111. DOI: 10.1038/sj.embor.7400452. View

3.

Hirose T, Fujii R, Nakamura H, Aratani S, Fujita H, Nakazawa M . Regulation of CREB-mediated transcription by association of CDK4 binding protein p34SEI-1 with CBP. Int J Mol Med. 2003; 11(6):705-12. View

4.

Hoglund M, Gorunova L, Andren-Sandberg A, Dawiskiba S, Mitelman F, Johansson B . Cytogenetic and fluorescence in situ hybridization analyses of chromosome 19 aberrations in pancreatic carcinomas: frequent loss of 19p13.3 and gain of 19q13.1-13.2. Genes Chromosomes Cancer. 1998; 21(1):8-16. View

5.

Klener P, Szynal M, Cleuter Y, Merimi M, Duvillier H, Lallemand F . Insights into gene expression changes impacting B-cell transformation: cross-species microarray analysis of bovine leukemia virus tax-responsive genes in ovine B cells. J Virol. 2006; 80(4):1922-38. PMC: 1367148. DOI: 10.1128/JVI.80.4.1922-1938.2006. View

6.

Bennetts J, Fowles L, Berkman J, van Bueren K, Richman J, Simpson F . Evolutionary conservation and murine embryonic expression of the gene encoding the SERTA domain-containing protein CDCA4 (HEPP). Gene. 2006; 374:153-65. DOI: 10.1016/j.gene.2006.01.027. View

7.

Sim K, Cheong J, Hsu S . The TRIP-Br family of transcriptional regulators is essential for the execution of cyclin E-mediated cell cycle progression. Cell Cycle. 2006; 5(10):1111-5. DOI: 10.4161/cc.5.10.2797. View

8.

Guy C, Zhou W, Kaufman S, ROBINSON M . E2F-1 blocks terminal differentiation and causes proliferation in transgenic megakaryocytes. Mol Cell Biol. 1996; 16(2):685-93. PMC: 231048. DOI: 10.1128/MCB.16.2.685. View

9.

Sham J, Fang Y, Sun L, Qin L, Wu Q, Xie D . Recurrent chromosome alterations in primary ovarian carcinoma in Chinese women. Cancer Genet Cytogenet. 2002; 133(1):39-44. DOI: 10.1016/s0165-4608(01)00567-2. View

10.

Turk R, Sterrenburg E, van der Wees C, de Meijer E, de Menezes R, Groh S . Common pathological mechanisms in mouse models for muscular dystrophies. FASEB J. 2005; 20(1):127-9. DOI: 10.1096/fj.05-4678fje. View

11.

Hayashi R, Goto Y, Ikeda R, Yokoyama K, Yoshida K . CDCA4 is an E2F transcription factor family-induced nuclear factor that regulates E2F-dependent transcriptional activation and cell proliferation. J Biol Chem. 2006; 281(47):35633-48. DOI: 10.1074/jbc.M603800200. View

12.

Hsu S, Yang C, Sim K, Hentschel D, OLeary E, Bonventre J . TRIP-Br: a novel family of PHD zinc finger- and bromodomain-interacting proteins that regulate the transcriptional activity of E2F-1/DP-1. EMBO J. 2001; 20(9):2273-85. PMC: 125435. DOI: 10.1093/emboj/20.9.2273. View

13.

Zhang D, Salto-Tellez M, Do E, Putti T, Koay E . Evaluation of HER-2/neu oncogene status in breast tumors on tissue microarrays. Hum Pathol. 2003; 34(4):362-8. DOI: 10.1053/hupa.2003.60. View

14.

Salto-Tellez M, Peh B, Ito K, Tan S, Chong P, Han H . RUNX3 protein is overexpressed in human basal cell carcinomas. Oncogene. 2006; 25(58):7646-9. DOI: 10.1038/sj.onc.1209739. View

15.

Calgaro S, Boube M, Cribbs D, Bourbon H . The Drosophila gene taranis encodes a novel trithorax group member potentially linked to the cell cycle regulatory apparatus. Genetics. 2002; 160(2):547-60. PMC: 1461966. DOI: 10.1093/genetics/160.2.547. View

16.

Zang Z, Sim K, Cheong J, Yang C, Yap C, Hsu S . Exploiting the TRIP-Br family of cell cycle regulatory proteins as chemotherapeutic drug targets in human cancer. Cancer Biol Ther. 2007; 6(5):712-8. DOI: 10.4161/cbt.6.5.3964. View

17.

Sugimoto M, Nakamura T, Ohtani N, Hampson L, Hampson I, Shimamoto A . Regulation of CDK4 activity by a novel CDK4-binding protein, p34(SEI-1). Genes Dev. 1999; 13(22):3027-33. PMC: 317153. DOI: 10.1101/gad.13.22.3027. View

18.

Soo R, Wu J, Aggarwal A, Tao Q, Hsieh W, Putti T . Celecoxib reduces microvessel density in patients treated with nasopharyngeal carcinoma and induces changes in gene expression. Ann Oncol. 2006; 17(11):1625-30. DOI: 10.1093/annonc/mdl283. View

19.

Tang D, Hu L, Xie D, Wu Q, Fang Y, Zeng Y . Oncogenic transformation by SEI-1 is associated with chromosomal instability. Cancer Res. 2005; 65(15):6504-8. DOI: 10.1158/0008-5472.CAN-05-0351. View

20.

Tomayko M, Reynolds C . Determination of subcutaneous tumor size in athymic (nude) mice. Cancer Chemother Pharmacol. 1989; 24(3):148-54. DOI: 10.1007/BF00300234. View